Eastman Chemical Company filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC, reporting third-quarter sales of $2.385 billion and net earnings attributable to Eastman of $252 million.

Key Highlights

  • Third-quarter sales of $2.385 billion, up from $2.202 billion in the third quarter of 2025, according to the filing.
  • Net earnings attributable to Eastman of $252 million in Q3 2026, compared with $69 million in Q3 2025.
  • Diluted earnings per share of $2.19 for Q3 2026, versus $0.60 in Q3 2025.
  • First nine months sales of $7.075 billion, compared with $6.779 billion for the first nine months of 2025.
  • Benefit from income taxes of $4 million in Q3 2026, contrasting with a provision of $65 million in Q3 2025.
  • 114,380,456 shares of common stock outstanding as of September 30, 2026, per the filing.

Eastman Chemical's Third-Quarter 2026 Financial Results

According to the Form 10-Q filed for the period ended September 30, 2026, Eastman Chemical Company (NYSE:EMN) reported third-quarter sales of $2.385 billion, an increase from $2.202 billion in the same quarter of 2025. Gross profit for Q3 2026 was $532 million, compared with $433 million in Q3 2025. Earnings before interest and taxes reached $305 million in the third quarter of 2026, up from $188 million in Q3 2025.

The filing reported net earnings attributable to Eastman of $252 million for Q3 2026, compared with $69 million in Q3 2025. Basic earnings per share attributable to Eastman were $2.21 for the third quarter of 2026, and diluted earnings per share were $2.19, versus $0.60 on both a basic and diluted basis in Q3 2025. The company reported a benefit from income taxes of $4 million in Q3 2026, compared with a provision for income taxes of $65 million in the prior-year quarter.

For the first nine months of 2026, the filing disclosed sales of $7.075 billion against $6.779 billion for the same period of 2025. Net earnings attributable to Eastman for the nine-month period were $542 million, compared with $391 million in the first nine months of 2025. Diluted earnings per share for the nine-month period were $4.70, versus $3.38 in the comparable 2025 period. The filing also noted asset impairments, restructuring, and other charges, net, of $10 million for the first nine months of 2026, compared with $42 million for the first nine months of 2025. The filing contains forward-looking statements that are the company's own and subject to its cautionary language as described in the filing.

What Was Disclosed

Eastman Chemical Company disclosed its unaudited consolidated financial results for the quarter and nine months ended September 30, 2026, including income statement figures, per-share amounts, and share count data, in a Form 10-Q filed with the SEC.